A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable ... Such forward-looking statements are estimates reflecting the Company's best ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global ...

In its first-ever GLP-1 study in humans reported in January ... Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number ...

3 “What they are best known for in the popular media is their effect on weight loss. While older medications for diabetes ...

Research has suggested that GLP-1 receptors in the brain may play a role in regulating ... Cedars-Sinai’s research team ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...